Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD recommends Promensil claims changes

This article was originally published in The Tan Sheet

Executive Summary

Natrol's advertising for Promensil red clover dietary supplement for relief of menopause symptoms "overstates the results" of research used to back its claims and the firm should modify them accordingly, the National Advertising Division of the Council of Better Business Bureaus states Sept. 18. NAD reviewed claims including, "Why Promensil ... 22 clinical studies can't be wrong," and "Clinically Proven and Doctor Recommended." The group examined Natrol's research and found conflicting efficacy research and deficiencies in the study data provided by the Chatsworth, Calif.-based firm. However, Natrol provided a reasonable basis to make certain limited claims that Promensil can help relieve the frequency and/or severity of hot flashes, increase testosterone to alleviate certain mood swings and promote breast and heart health, NAD says. The CBBB group recommends Natrol discontinue the use of "Clinically Proven" phrase due to insufficient evidence and modify the "Doctor Recommended" claims to clearly disclose that physicians from Australia and Canada were used in the product's research. The NAD recommendations come after the Center for Science in the Public Interest expressed its concerns with the supplement's ads and labels claims calling for federal intervention (1"The Tan Sheet" Sept. 17, 2007, In Brief)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel